Loading
waveLINE-003 tests a ROR1-directed ADC added to standard salvage chemotherapy.
waveLINE-003, trial NCT05139017 sponsored by Merck, is a phase 2/3 trial testing the ROR1-directed antibody-drug conjugate zilovertamab vedotin, also known as MK-2140, added to rituximab, gemcitabine and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma after at least one line, in transplant-ineligible or post-transplant patients. A companion frontline trial, waveLINE-010, tests the drug with R-CHP. OnCo links it to lymphoma, ROR1 as a target and zilovertamab vedotin. It is recruiting with no results, and whether ROR1, a target without an approved drug, can be exploited safely with an ADC is the question it exists to answer.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD).
Shares ROR1, Diffuse large B-cell lymphoma.
Shares ROR1, Zilovertamab vedotin, Antibody-drug conjugate (ADC).